- Home
- IONS vs INTA Comparison
IONS vs INTA Comparison
Compare IONS & INTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- INTA
- Stock Information
- Founded
- IONS 1989
- INTA 2000
- Country
- IONS United States
- INTA United States
- Employees
- IONS N/A
- INTA N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- INTA Computer Software: Prepackaged Software
- Sector
- IONS Health Care
- INTA Technology
- Exchange
- IONS Nasdaq
- INTA Nasdaq
- Market Cap
- IONS 6.0B
- INTA 5.2B
- IPO Year
- IONS 1991
- INTA 2021
- Fundamental
- Price
- IONS $31.43
- INTA $67.48
- Analyst Decision
- IONS Buy
- INTA Buy
- Analyst Count
- IONS 18
- INTA 12
- Target Price
- IONS $62.00
- INTA $60.60
- AVG Volume (30 Days)
- IONS 1.5M
- INTA 701.6K
- Earning Date
- IONS 02-19-2025
- INTA 02-04-2025
- Dividend Yield
- IONS N/A
- INTA N/A
- EPS Growth
- IONS N/A
- INTA N/A
- EPS
- IONS N/A
- INTA N/A
- Revenue
- IONS $803,067,000.00
- INTA $447,753,000.00
- Revenue This Year
- IONS N/A
- INTA $17.88
- Revenue Next Year
- IONS $10.85
- INTA $14.87
- P/E Ratio
- IONS N/A
- INTA N/A
- Revenue Growth
- IONS 30.57
- INTA 20.07
- 52 Week Low
- IONS $31.41
- INTA $30.36
- 52 Week High
- IONS $52.49
- INTA $71.34
- Technical
- Relative Strength Index (RSI)
- IONS 33.19
- INTA 58.97
- Support Level
- IONS $32.61
- INTA $65.31
- Resistance Level
- IONS $35.37
- INTA $68.62
- Average True Range (ATR)
- IONS 1.28
- INTA 2.49
- MACD
- IONS -0.30
- INTA 0.05
- Stochastic Oscillator
- IONS 0.36
- INTA 85.19
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, investment banking, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.